



## Usefulness of home sleep apnea tests in heart failure patients

Inês Araújo<sup>1,2</sup>  • Cândida Fonseca<sup>1,2</sup>

Received: 16 February 2019 / Accepted: 3 March 2019 / Published online: 14 March 2019  
© Springer Nature Switzerland AG 2019

To the Editor:

We thank Dr. Mukesh Kapoor for his comments concerning our study [1]. We are in agreement that home sleep apnea testing is cost-effective and time saving for the majority of heart failure patients. In our country, we have no problems with insurances but the waiting list for a polysomnography is rather unacceptable.

Our study has validated the *ApneaLink Plus* device for the detection of sleep apnea, which is the device that we use. If other portable devices are to be used, they should first undergo a validation process for the new device and for the population to be tested.

Other aspect approached was the fact that we did not aim to distinguish between central sleep apnea (CSA) and obstructive sleep apnea (OSA). In fact, as we know, CSA in heart failure patients is prevalent in worst NYHA classes, especially in those with reduced ejection fraction, and its presence relates to a worse prognosis. However, CSA does not have an effective treatment. SERVE-HF study has shown that treating these patients with servo-ventilation is harmful, with a rise in mortality rate [2]. Results of the Canadian Continuous Positive Airway Pressure (CPAP) for Patients with Central Sleep Apnea and Heart Failure trial were neutral in the whole population [3] and a *post hoc* analysis showed that CPAP had a beneficial effect in CSA patients who respond to CPAP therapy [4]. So, only OSA has a formal indication for treatment in heart failure patients [5]. Heart failure pa-

tients should be tested when stable. The majority of heart failure patients have both OSA and CSA. By starting CPAP therapy in patients with  $AHI > 15$  events/hour in *ApneaLink Plus* report, OSA will be properly and timely treated while CPAP will not be a wrong option for CSA and it might even be beneficial according to the results of the *post hoc* study mentioned above [4]. Those patients who do not respond to CPAP therapy should subsequently undergo a polysomnography to further clarify the sleep apnea type. Using this flowchart, only a minority of patients will need to obtain a polysomnography.

In conclusion, by using validated portable devices to diagnose sleep apnea, we are saving money and time and we will be able to treat who is really treatable.

## References

1. Araújo I, Marques F, André S, Araújo M, Marques S, Ferreira R, Moniz P, Proença M, Borrego P, Fonseca C (2018) Diagnosis of sleep apnea in patients with stable chronic heart failure using a portable sleep test diagnostic device. *Sleep Breath* 22(3):749–755. <https://doi.org/10.1007/s11325-017-1607-1>
2. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E, Levy P, Simonds AK, Somers VK, Zannad F, Teschler H (2015) Adaptive servo-ventilation for central sleep apnea in systolic heart failure. *N Engl J Med* 373(12):1095–1105. <https://doi.org/10.1056/NEJMoa1506459>
3. Bradley TD, Logan AG, Kimoff RJ, Séries F, Morrison D, Ferguson K, Belenkie I, Pfeifer M, Fleetham J, Hanly P, Smilovitch M, Tomlinson G, Floras JS, CANPAP Investigators (2005) Continuous positive airway pressure for central sleep apnea and heart failure. *N Engl J Med* 353(19):2025–2033. <https://doi.org/10.1056/NEJMoa051001>
4. Arzt M, Floras JS, Logan AG, Kimoff RJ, Séries F, Morrison D, Ferguson K, Belenkie I, Pfeifer M, Fleetham J, Hanly P, Smilovitch M, Ryan C, Tomlinson G, Bradley TD, CANPAP Investigators (2007) Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a *post hoc* analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). *Circulation* 115(25):3173–3180. <https://doi.org/10.1161/CIRCULATIONAHA.106.683482>

✉ Inês Araújo  
inesarauj@gmail.com

<sup>1</sup> Heart Failure Unit, Internal Medicine Department, São Francisco Xavier Hospital – Western Lisbon Hospital Centre (CHLO), Estrada do Forte do Alto do Duque, 1449-005 Lisbon, Portugal

<sup>2</sup> NOVA Medical School, Faculty of Medical Sciences, New University of Lisbon, Campo Mártires da Pátria 130, 1169-056 Lisbon, Portugal

5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members; Document Reviewers (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and

chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 18(8): 891–975. <https://doi.org/10.1002/ejhf.592>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.